Goldman Sachs Downgrades Halozyme Therapeutics (HALO) to Neutral, 'Royalty growth trajectory understood from here'

July 24, 2023 3:02 AM EDT Send to a Friend
(Updated - July 24, 2023 4:40 AM EDT)

Goldman Sachs analyst Corinne Jenkins downgraded Halozyme Therapeutics (NASDAQ: HALO) from ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login